EUVIMEDEUVIMED entdecken
Fallbericht

Novel Endobronchial Valve: A Case Series on the Technical Feasibility of the PulmValve in Severe Heterogeneous Emphysema

Difei Chen, Jingwei Liu, Weizhan Luo, Lianyue Yang, Jinsheng Lin, Jing Zhang, Shiyue Li

Respiration · 08.06.2026 · 1-9

DOI: 10.1159/000552824 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Respiration, online erschienen am 08.06.2026. Verfasst von Difei Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Th…. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bronchoscopic lung volume reduction with endobronchial valves is an established therapy for selected patients with severe heterogeneous emphysema. The PulmValve is a novel lobar endobronchial valve designed to achieve occlusion with larger-diameter valves. We present here its first-in-human exploratory experience. Case Presentation: Six male patients underwent successful lobar valve implantation, with a median of 1 valve per treated lobe. No intraprocedural complications, device malfunctions, or valve migration were observed during follow-up. Four serious adverse events occurred, including 1 hydropneumothorax, 1 acute exacerbation of chronic obstructive pulmonary disease, 1 pulmonary infection in a non-treated lobe, and 1 sudden cardiac death. The fatal event was adjudicated as possibly unrelated. Early improvement in dyspnea was noted in most patients. Compared to baseline, at 3 months, forced expiratory volume in 1 s improved by 80 mL (30–310) and residual volume decreased by 200 mL (−890 to 430), accompanied by 6-min walk test increased by 34 m (−34 to 71) and St. George’s Respiratory Questionnaire score dropped by 16 points (−4 to 23). At 6 months, pulmonary function changes were variable, while exercise capacity and symptom scores remained improved in selected cases.

Conclusion

In this exploratory first-in-human case series, lobar PulmValve implantation was technically feasible and generated descriptive clinical signals. Larger controlled studies are required to define safety, durability, and clinical efficacy.

Schlagwörter

Stichwörter der Autor:innen

Chronic obstructive pulmonary diseaseEmphysemaEndobronchial valvesEndoscopic lung volume reduction

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
  • MedTecX, Shanghai, China.

Zitieren

APA

Chen, D., Liu, J., Luo, W., Yang, L., Lin, J., Zhang, J., & Li, S. (2026). Novel Endobronchial Valve: A Case Series on the Technical Feasibility of the PulmValve in Severe Heterogeneous Emphysema. Respiration, 1-9. https://doi.org/10.1159/000552824

Vancouver

Chen D, Liu J, Luo W, Yang L, Lin J, Zhang J, et al. Novel Endobronchial Valve: A Case Series on the Technical Feasibility of the PulmValve in Severe Heterogeneous Emphysema. Respiration. 2026:1-9. doi:10.1159/000552824

BibTeX
@article{Chen2026,
  author = {Chen, Difei and Liu, Jingwei and Luo, Weizhan and Yang, Lianyue and Lin, Jinsheng and Zhang, Jing and Li, Shiyue},
  title = {Novel Endobronchial Valve: A Case Series on the Technical Feasibility of the PulmValve in Severe Heterogeneous Emphysema},
  journal = {Respiration},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000552824}
}
Kostenlos starten →